Evidence map›Paper›PMID 31625131›Full record

ArticleAdvances in therapy2019

Gender Disparities in Health Resource Utilization in Patients with Atherosclerotic Cardiovascular Disease: A Retrospective Cross-Sectional Study.

Xian Shen, Stefan DiMario, Kiran Philip

Open access · hybridAbstract read
In one paragraph

Article in Advances in therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Italian Association of Hospital Cardiologists Position Paper 'Gender discrepancy: time to implement gender-based clinical management'.European heart journal supplements : journal of the European Society of Cardiology · 2024
    Article
  6. Review
  7. Evaluation and management of blood lipids through a woman's life cycle.American journal of preventive cardiology · 2022
    Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Xian ShenAvalere Health, Washington, DC, USA. shenxian.1029@gmail.com.
Stefan DiMarioAmgen Inc, Thousand Oaks, CA, USA.
Kiran PhilipAmgen Inc, Thousand Oaks, CA, USA.
Amgen (United States) · USPrevea Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGender disparities in access to healthcare have been documented, including disparities in access to care for cardiovascular diseases (CVDs). Disparities in access to cardiologists could disadvantage some patients to the newer lipid-lowering proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) antibodies, as utilization management criteria for PCSK9is often require step therapy with statins and/or ezetimibe and prescription by a cardiologist. To assess whether these utilization management criteria disproportionally limit access to patients with certain characteristics, we assessed the use of cardiologist care and receipt of statin and/or ezetimibe prescriptions from a cardiologist by gender and other patient demographic and clinical characteristics.

methodsThis cross-sectional study used administrative claims data from Inovalon's Medical Outcomes Research for Effectiveness and Economics Registry (MORE

resultsData from 39,322 patients in commercial plans and 261,898 patients with Medicare Advantage were analyzed. Female gender (vs male) was associated with a significantly lower likelihood of visiting a cardiologist for patients in commercial plans (odds ratio [OR] 0.85; 95% confidence limit [CL] 0.81-0.88) and in Medicare Advantage plans (OR 0.82; 95% CL 0.81-0.83). Female gender was also associated with a lower likelihood of receiving a statin and/or ezetimibe prescription from a cardiologist for patients in commercial plans (OR 0.69; 95% CL 0.65-0.74) and in Medicare Advantage plans (OR 0.78; 95% CL 0.76-0.79).

conclusionsCompared with men, women were less likely to visit a cardiologist and less likely to receive a prescription for a statin and/or ezetimibe from a cardiologist.

fundingAmgen Inc.

Indexed as

PCSK9 InhibitorsAgedAtherosclerosisCardiologistsCross-Sectional StudiesEzetimibeFemaleHealth ResourcesHealth ServicesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsMaleMedicare Part CMiddle AgedPatient Acceptance of Health CareEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsPCSK9 InhibitorsSubtilisinCardiologyClaims analysisEquityEzetimibeGenderHealthcare utilizationPCSK9 inhibitorStatin

Identifiers

PMID31625131
PMCPMC6860468
OpenAlexW2980404147

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.